Addressing the country digitally, the Prime Minister said that India managed to make two 'Made-in-India' vaccines in a very short period which usually takes years.
So far, the government has procured 1.1 crore Covishield and 55 lakh Covaxin vaccines at a cost of Rs 200 and Rs 206 per dose, respectively.
The world's biggest vaccination drives comes almost a year after the first coronavirus case was detected in India, which then claimed over 1.5 lakh lives and infected one crore people.
58 healthcare centres ready to provide emergency services to individuals with Adverse Events Following Immunisation across State
The trial will be conducted on 1,500 subjects as part of the randomised, double-blind, parallel-group, placebo-controlled study in India
Modi to launch nationwide drive through video link; 4,000 TS health staff to get inoculated at 139 centres on Day 1
A total of 14 centres have been identified for vaccination in Karimnagar, Jagitial, Peddapalli and Rajanna-Sircilla districts on the first day of vaccination process from Saturday
"Covishield and Covaxin, the two COVID-19 vaccines which have received Emergency Use Authorisation (EAU) have been tested on thousands of people and side-effects are negligible"
The supplies of Covaxin will be prioritised for public market through direct procurement by Brazil government while the supplies to private market would be based upon receipt of market authorisation from the country's regulator
The Drugs Controller General of India on Sunday gave the permission to Bharat Biotech's Covaxin for use in an emergency situation.
The approval to Covaxin has been questioned by industry experts and some opposition Congress leaders who have expressed concern over the absence of phase 3 trial data
While this vaccine addresses an unmet medical need during this pandemic, our goal is to provide global access to populations that need it the most. Covaxin has generated excellent safety data with robust immune responses
Covaxin is being developed by Bharat Biotech jointly with the Indian Council of Medical Research (ICMR)- National Institute of Virology (NIV).
The final decision on its approval will, however, be taken by the Drug Controller General of India (DCGI)